Anticancer Ether Lipids
Journal of Medicinal Chemistry, 2005, Vol. 48, No. 23 7313
(23) Jensen, S. S.; Andresen, T. L.; Davidsen, J.; Høyrup, P.; Shnyder,
S. D.; Bibby, M. C.; Gill, J. H.; Jørgensen, K. Secretory phos-
pholipase A2 as a tumor-specific trigger for targeted delivery of
a novel class of liposomal prodrug anticancer etherlipids. Mol.
Cancer Ther. 2004, 3, 1451-1458.
(24) Abe, T.; Sakamoto, K.; Kamohara, H.; Hirano, Y.; Kuwahara,
N.; Ogawa, M. Group II phospholipase A2 is increased in
peritoneal and pleural effusions in patients with various types
of cancer. Int. J. Cancer 1997, 74, 245-250.
(25) Graff, J. R.; Konicek, B. W.; Deddens, J. A.; Chedid, M.; Hurst,
B. M.; Colligan, B.; Neubauer, B. L.; Carter, H. W.; Carter, J.
H. Expression of group IIa secretory phospholipase A2 increases
with prostate tumor grade. Clin. Cancer Res. 2001, 7, 3857-3861.
(26) Murakami, M.; Kudo, I. Phospholipase A2. J. Biochem. (Tokyo)
2002, 131, 285-292.
(27) Yamashita, S.; Yamashita, J.; Sakamoto, K.; Inada, K.; Na-
kashima, Y.; Murata, K.; Saishoji, T.; Nomura, K.; Ogawa, M.
Increased expression of membrane-associated phospholipase-A2
shows malignant potential of human breast-cancer cells. Cancer
1993, 71, 3058-3064.
(28) Murata, K.; Egami, H.; Kiyohara, H.; Oshima, S.; Kurizaki, T.;
Ogawa, M. Expression of group-II phospholipase-A2 in malig-
nant and nonmalignant human gastric-mucosa. Br. J. Cancer
1993, 68, 103-111.
(29) Leung, S. Y.; Chen, X.; Chu, K. M.; Yuen, S. T.; Mathy, J.; Ji, J.
F.; Chan, A. S. Y.; Li, R.; Law, S.; Troyanskaya, O. G.; Tu, I. P.;
Wong, J.; So, S.; Botstein, D.; Brown, P. O. Phospholipase A2
group IIA expression in gastric adenocarcinoma is associated
with prolonged survival and less frequent metastasis. Proc. Natl.
Acad. Sci. U.S.A. 2002, 99, 16203-16208.
(30) Praml, C.; Amler, L. C.; Dihlmann, S.; Finke, L. H.; Schlag, P.;
Schwab, M. Secretory Type II Phospholipase A(2) (PLA2G2A)
expression status in colorectal carcinoma derived cell lines and
in normal colonic mucosa. Oncogene 1998, 17, 2009-2012.
(31) Edhemovic, I.; Snoj, M.; Kljun, A.; Golouh, R. Immunohis-
tochemical localization of group II phospholipase A2 in the
tumours and mucosa of the colon and rectum. Eur. J. Surg.
Oncol. 2001, 27, 545-548.
(32) Kennedy, B. P.; Soravia, C.; Moffat, J.; Xia, L.; Hiruki, T.; Collins,
S.; Gallinger, S.; Bapat, B. Overexpression of the nonpancreatic
secretory group II PLA(2) messenger RNA and protein in
colorectal adenomas from familial adenomatous polyposis pa-
tients. Cancer Res. 1998, 58, 500-503.
(45) Jurczak, J.; Pikul, S.; Bauer, T. (R)-2,3-O-Isopropylideneglyc-
eraldehyde and (S)-2,3-O-isopropylideneglyceraldehyde in ste-
reoselective organic synthesis. Tetrahedron 1986, 42, 447-488.
(46) Schmid, C. R.; Bryant, J. D.; Dowlatzedah, M.; Phillips, J. L.;
Prather, D. E.; Schantz, R. D.; Sear, N. L.; Vianco, C. S.
Synthesis of 2,3-O-isopropylidene-D-glyceraldehyde in high
chemical and optical purity - Observations on the development
of a practical bulk process. J. Org. Chem. 1991, 56, 4056-4058.
(47) Hirth, G.; Barner, R. Synthesis of glyceryl etherphosphatides.
1. Preparation of 1-O-octadecyl-2-O-acetyl-sn-glyceryl-3-phos-
phorylcholine (Platelet Activating Factor), of its enantiomer and
of some analogous compounds. Helv. Chim. Acta 1982, 65, 1059-
1084.
(48) Shin, J.; Gerasimov, O.; Thompson, D. H. Facile synthesis of
plasmalogens via Barbier-type reactions of vinyl dioxanes and
vinyl dioxolanes with alkyl halides in LiDBB solution. J. Org.
Chem. 2002, 67, 6503-6508.
(49) Qin, D. H.; Byun, H. S.; Bittman, R. Synthesis of plasmalogen
via 2,3-bis-O-(4′-methoxybenzyl)-sn-glycerol. J. Am. Chem. Soc.
1999, 121, 662-668.
(50) Martin, S. F.; Josey, J. A.; Wong, Y. L.; Dean, D. W. General-
method for the synthesis of phospholipid derivatives of 1,2-
diacyl-sn-glycerols. J. Org. Chem. 1994, 59, 4805-4820.
(51) Guivisdalsky, P. N.; Bittman, R. Novel enantioselective synthesis
of platelet activating factor and its enantiomer via ring-opening
of glycidyl tosylate with 1-hexadecanol. Tetrahedron Lett. 1988,
29, 4393-4396.
(52) Guivisdalsky, P. N.; Bittman, R. An efficient stereocontrolled
route to both enantiomers of Platelet Activating Factor and
analogues with long chain esters at C2 - Saturated and
unsaturated ether glycerolipids by opening of glycidyl arene-
sulfonates. J. Org. Chem. 1989, 54, 4643-4648.
(53) Lindberg, J.; Ekeroth, J.; Konradsson, P. Efficient synthesis of
phospholipids from glycidyl phosphates. J. Org. Chem. 2002, 67,
194-199.
(54) Chupin, V. V.; Ostapenko, O. V.; Klykov, V. N.; Anikin, M. V.;
Serebrennikova, G. A. Formation of a structural isomer of
Platelet-Activing-Factor during 1-alkyl-sn-glycero-3-phospho-
choline acetylation. Bioorg. Khim. 1993, 19, 1111-1121.
(55) Boden, N.; Bushby, R. J.; Liu, Q. Y.; Evans, S. D.; Jenkins, T.
A.; Miles, R. E. N, N′-Disuccinimidyl carbonate as a coupling
agent in the synthesis of thiophospholipids used for anchoring
biomembranes to gold surfaces. Tetrahedron 1998, 54, 11537-
11548.
(56) Chen, Y. S.; Zhang, W.; Chen, X.; Wang, J. Q.; Wang, P. G. alpha
Gal-conjugated anti-rhinovirus agents: chemo-enzymatic syn-
theses and testing of anti-Gal binding. J. Chem. Soc., Perkin
Trans. 1 2001, 1716-1722.
(57) Delfino, J. M.; Schreiber, S. L.; Richards, F. M. An efficient
method for the partial synthesis of mixed-chain phosphatidyle-
thanolamines. Tetrahedron Lett. 1987, 28, 2327-2330.
(58) Murakami, K.; Molitor, E. J.; Liu, H. W. An efficient synthesis
of unsymmetrical optically active phosphatidyl glycerol. J. Org.
Chem. 1999, 64, 648-651.
(33) Kashiwagi, M.; Friess, H.; Uhl, W.; Berberat, P.; Abou-Shady,
M.; Martignoni, M.; Anghelacopoulos, S. E.; Zimmermann, A.;
Buchler, M. W. Group II and IV phospholipase A(2) are produced
in human pancreatic cancer cells and influence prognosis. Gut
1999, 45, 605-612.
(34) Jiang, J.; Neubauer, B. L.; Graff, J. R.; Chedid, M.; Thomas, J.
E.; Roehm, N. W.; Zhang, S.; Eckert, G. J.; Koch, M. O.; Eble, J.
N.; Cheng, L. Expression of group IIA secretory phospholipase
A2 is elevated in prostatic intraepithelial neoplasia and adeno-
carcinoma. Am. J. Pathol. 2002, 160, 667-671.
(35) Ying, Z.; Tojo, H.; Komatsubara, T.; Nakagawa, M.; Inada, M.;
Kawata, S.; Matsuzawa, Y.; Okamoto, M. Enhanced expression
of group-II phospholipase A(2) in human hepatocellular-carci-
noma. Biochim. Biophys. Acta 1994, 1226, 201-205.
(36) Houlihan, W. J.; Lohmeyer, M.; Workman, P.; Cheon, S. H.
Phospholipid antitumor agents. Med. Res. Rev. 1995, 15, 157-223.
(37) Ahmad, I.; Filep, J. J.; Franklin, J. C.; Janoff, A. S.; Masters,
G. R.; Pattassery, J.; Peters, A.; Schupsky, J. J.; Zha, Y.;
Mayhew, E. Enhanced therapeutic effects of liposome-associated
1-O-octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer
Res. 1997, 57, 1915-1921.
(38) Ruiter, G. A.; Zerp, S. F.; Bartelink, H.; van Blitterswijk, W. J.;
Verheij, M. Anti-cancer alkyl-lysophospholipids inhibit the phos-
phatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer
Drugs 2003, 14, 167-173.
(39) Eue, I. Growth inhibition of human mammary carcinoma by
liposomal hexadecylphosphocholine: Participation of activated
macrophages in the antitumor mechanism. Int. J. Cancer 2001,
92, 426-433.
(40) Vivanco, I.; Sawyers, C. L. The phosphatidylinositol 3-kinase-
AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2, 489-
501.
(41) Cantley, L. C.; Neel, B. G. New insights into tumor suppres-
sion: PTEN suppresses tumor formation by restraining the
phosphoinositide 3-kinase AKT pathway. Proc. Natl. Acad. Sci.
U.S.A. 1999, 96, 4240-4245.
(42) Peters, U.; Bankova, W.; Welzel, P. Platelet-Activating-Factor
synthetic studies. Tetrahedron 1987, 43, 3803-3816.
(43) Massing, U.; Eibl, H. New optically pure dimethylacetals of
glyceraldehydes and their application for lipid and phospholipid
synthesis. Chem. Phys. Lipids 1995, 76, 211-224.
(44) Massing, U.; Eibl, H. Synthesis of enantiomerically pure 1-O-
phosphocholine-2-O-acyl-octadecane and 1-O-phosphocholine-2-
N-acyl-octadecane. Chem. Phys. Lipids 1994, 69, 105-120.
(59) Hendrickson, E. K.; Hendrickson, H. S. Efficient synthesis of
the cholinephosphate phospholipid headgroup. Chem. Phys.
Lipids 2001, 109, 203-207.
(60) Watanabe, Y.; Tomioka, M.; Ozaki, S. Synthesis of 1D-di-
astearoylphosphatidyl-myo-inositol 3,4,5-tris(dihydrogen phos-
phate). Tetrahedron 1995, 51, 8969-8976.
(61) Brown, P.; Richardson, C. M.; Mensah, L. M.; O’Hanlon, P. J.;
Osborne, N. F.; Pope, A. J.; Walker, G. Molecular recognition of
tyrosinyl adenylate analogues by prokaryotic tyrosyl tRNA
synthetases. Bioorg. Med. Chem. 1999, 7, 2473-2485.
(62) Kubiak, R. J.; Bruzik, K. S. Comprehensive and uniform
synthesis of all naturally occurring phosphorylated phosphati-
dylinositols. J. Org. Chem. 2003, 68, 960-968.
(63) Andresen, T. L.; Skytte, D. M.; Madsen, R. Synthesis of anti-
tumour phosphatidylinositol analogues from glucose by the use
of ring-closing olefin metathesis. Org. Biomol. Chem. 2004, 2,
2951-2957.
(64) Carmichael, J.; DeGraff, W. G.; Gazdar, A. F.; Minna, J. D.;
Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated
colorimetric assay: assessment of chemosensitivity testing.
Cancer Res. 1987, 47, 936-942.
(65) Lohmeyer, M.; Workman, P. Growth arrest vs direct cytotoxicity
and the importance of molecular structure for the in vitro anti-
tumour activity of ether lipids. Br. J. Cancer 1995, 72, 277-286.
(66) Castillo, S. S.; Brognard, J.; Petukhov, P. A.; Zhang, C.; Tsuru-
tani, J.; Granville, C. A.; Li, M.; Jung, M.; West, K. A.; Gills, J.
G.; Kozikowski, A. P.; Dennis, P. A. Preferential inhibition of
Akt and killing of Akt-dependent cancer cells by rationally
designed phosphatidylinositol ether lipid analogues. Cancer Res.
2004, 64, 2782-2792.
(67) Yamashita, S.; Ogawa, M.; Sakamoto, K.; Abe, T.; Arakawa, H.;
Yamashita, J. Elevation of serum group II phospholipase A2
levels in patients with advanced cancer. Clin. Chim. Acta 1994,
228, 91-99.